Why is There So Much Attention on Obesity Drugs?
High U.S. prices and demand for Ozempic and Wegovy have implications for insurance premiums, public program costs, and affordability.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
High U.S. prices and demand for Ozempic and Wegovy have implications for insurance premiums, public program costs, and affordability.
Sen. Vance suggested moving higher-risk individuals to different insurance risk pools than healthier ones... What could such a policy mean for health coverage and costs?
Former President Trump has routinely blamed undocumented immigrants for a rise in drug trafficking and overdose deaths…But most fentanyl is being trafficked by American citizens. …
While public support for IVF is high, Congress has been unable to agree even on the right to get IVF services. Agreement on coverage and funding seem even more out of reach
The federal government has finalized significant updates to mental health parity requirements for employer health plans and individual private health insurance.
New poverty data show the supplemental poverty rate for children remains more than double what it was in 2021.
While former President Trump has stated that overturning Roe v. Wade turned the decision of abortion back to states and “the people are now deciding,” it is a complicated political and legal road
The fact that health reform has not been a central issue in this campaign does not mean that the outcome of the election has no consequences for health care.
The news today about the efficacy of a new long-acting injectable PrEP, the second such breakthrough announcement in recent months, is nothing short of groundbreaking.
Many physicians fear criminalization if state authorities challenge whether their patients qualify under the narrow and vague exceptions in state bans.
© 2026 KFF